Preliminary clinical data on a new photodynamic therapy photosensitizer: 2-[1-hexyloxyethyl]-2-devinylpyropheophorbide-a (HPPH) for treatment of obstructive esophageal cancer

Thomas J. Dougherty; R. K. Pandey; Hector R. Nava; Judy L. Smith; Harold O. Douglass; Stephen B. Edge; David A. Bellnier; Linda O'Malley; Michele Cooper

doi:10.1117/12.379876

29 March 2000 Preliminary clinical data on a new photodynamic therapy photosensitizer: 2-[1-hexyloxyethyl]-2-devinylpyropheophorbide-a (HPPH) for treatment of obstructive esophageal cancer

Thomas J. Dougherty, R. K. Pandey, Hector R. Nava, Judy L. Smith, Harold O. Douglass, Stephen B. Edge, David A. Bellnier, Linda O'Malley, Michele Cooper

Author Affiliations +

Proceedings Volume 3909, Optical Methods for Tumor Treatment and Detection: Mechanisms and Techniques in Photodynamic Therapy IX; (2000) https://doi.org/10.1117/12.379876
Event: BiOS 2000 The International Symposium on Biomedical Optics, 2000, San Jose, CA, United States

Abstract

Limited therapeutic options exist when chest wafl recurrence from breast cancer progresses despite standard salvage treatment. As photodynamic therapy offers excellent response for cutaneous lesions this may be a possible indication for PDT. A total of 1 02 treatment fields were illuminated on 9 women with biopsy proven chest wall recurrence of breast cancer which was progressing despite salvage surgery, radiation, and chemo-hormonal therapy. PDT consisted of outpatient IV infusion ofPhotofrmn at 0.8 mg/kg followed 48 hours later by illumination at 140-170 J/cm2 via a KTP Yag laser coupled to a dye unit. No patient was lost to follow up. At 6 months post PDT; complete response, defined as total lesion elimination was 89%, partial response 8%, and no response 3%. No photosensitivity was seen and no patient developed scarring, fibrosis, or healing difficulties. Low dose Photofrmn induced PDT is very active against chest wall lesions. Despite fragile and heavily pre-treated tissues, excellent clinical and cosmetic outcome was obtained. PDT is an underutilized modality for this indication.

Citation Download Citation

Thomas J. Dougherty, R. K. Pandey, Hector R. Nava, Judy L. Smith, Harold O. Douglass, Stephen B. Edge, David A. Bellnier, Linda O'Malley, and Michele Cooper "Preliminary clinical data on a new photodynamic therapy photosensitizer: 2-[1-hexyloxyethyl]-2-devinylpyropheophorbide-a (HPPH) for treatment of obstructive esophageal cancer", Proc. SPIE 3909, Optical Methods for Tumor Treatment and Detection: Mechanisms and Techniques in Photodynamic Therapy IX, (29 March 2000); https://doi.org/10.1117/12.379876

ACCESS THE FULL ARTICLE

INSTITUTIONAL
Select your institution to access the SPIE Digital Library.

SELECT YOUR INSTITUTION

PERSONAL
Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.

PERSONAL SIGN IN

No SPIE Account? Create one

PURCHASE THIS CONTENT

SUBSCRIBE TO DIGITAL LIBRARY

50 downloads per 1-year subscription

Members: $195

Non-members: $335 ADD TO CART

25 downloads per 1 - year subscription

Members: $145

Non-members: $250 ADD TO CART

PURCHASE SINGLE ARTICLE

Includes PDF, HTML & Video, when available